Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis

  1. Maralice E. Conacci-Sorrell1,
  2. Tamar Ben-Yedidia1,
  3. Michael Shtutman1,
  4. Elena Feinstein2,
  5. Paz Einat2, and
  6. Avri Ben-Ze'ev1,3
  1. 1Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel; 2QBI Enterprises Ltd., Nes Ziona, 74106, Israel

Abstract

β-catenin and plakoglobin (γ-catenin) are homologous molecules involved in cell adhesion, linking cadherin receptors to the cytoskeleton. β-catenin is also a key component of the Wnt pathway by being a coactivator of LEF/TCF transcription factors. To identify novel target genes induced by β-catenin and/or plakoglobin, DNA microarray analysis was carried out with RNA from cells overexpressing either protein. This analysis revealed that Nr-CAM is the gene most extensively induced by both catenins. Overexpression of either β-catenin or plakoglobin induced Nr-CAM in a variety of cell types and the LEF/TCF binding sites in the Nr-CAM promoter were required for its activation by catenins. Retroviral transduction of Nr-CAM into NIH3T3 cells stimulated cell growth, enhanced motility, induced transformation, and produced rapidly growing tumors in nude mice. Nr-CAM and LEF-1 expression was elevated in human colon cancer tissue and cell lines and in human malignant melanoma cell lines but not in melanocytes or normal colon tissue. Dominant negative LEF-1 decreased Nr-CAM expression and antibodies to Nr-CAM inhibited the motility of B16 melanoma cells. The results indicate that induction of Nr-CAM transcription by β-catenin or plakoglobin plays a role in melanoma and colon cancer tumorigenesis, probably by promoting cell growth and motility.

Keywords

Footnotes

  • 3 Corresponding author.

  • E-MAIL avri.ben-zeev{at}weizmann.ac.il; FAX 97-28-946-5261.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.227502.

    • Received February 11, 2002.
    • Accepted June 17, 2002.
| Table of Contents

Life Science Alliance